Related Experiment Video
Updated: May 26, 2026

A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
CEACAM1 in malignant melanoma: a diagnostic and therapeutic target
S Sapoznik1, R Ortenberg, J Schachter
1Ella Institute of Melanoma, Cancer Research Center, Sheba Medical Center 52621, Israel.
Abstract:
CEACAM1 adhesion molecule is broadly expressed, participates in pivotal cellular and immunological processes and is involved in cancer. Originally identified as a tumor suppressor, it is now known that in several cancers, including malignant melanoma, CEACAM1 expression correlates with tumor progression and poor survival. Here we review the findings connecting CEACAM1 to malignant melanoma, encompassing in-vitro, in-vivo and patients-derived data. A CEACAM1-mediated mechanism used by melanoma cells to evade immune attack is described in detail. Finally, the potential value of CEACAM1 as a melanoma biomarker and therapeutic target is being discussed.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...

